Using our IBD organoculture model, we can investigate the anti-inflammatory effects of your test drugs to treat Crohn's disease or ulcerative colitis. As inflammation is a defining feature of IBD, the tissue resections (ileum or colon) are received residual to surgery with inflamed areas of the intestine determined by a pathologist.
All tissues are rapidly transported to Reprocell as fresh living tissues 24/7 for processing at our laboratories in the USA or UK. Similar experiments can be conducted in non-human preclinical models of IBD to allow cross-species comparisons. The resultant organocultures can be exposed to a range of test agents for up to 24 hours:
More than 40 inflammatory mediators can be measured
Data from healthy, Crohn’s, and ulcerative colitis patients can be compared
Cross-species comparison studies, e.g. with other preclinical models of IBD
Tissue cytokine profiles correlate well with literature from clinical studies
End-point analysis includes multiplex ELISA/Luminex assay, gene expression (RT-PCR), or immunohistochemistry (IHC)
Image: Top, A fresh gut explant from an IBD patient. Bottom, End-point analysis being performed in our Glasgow laboratory.
